Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Vaginal Neoplasms 1Lymphoma, Follicular 1Glioblastoma 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

trastuzumab deruxtecan 1liposomal doxorubicin 1dostarlimab 1Therapeutic Touch 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Gemcitabine 1Doxorubicin 1Congresses as Topic 1Cisplatin 1Bupropion 1Brachytherapy 1Bevacizumab 1Axitinib 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaginal Neoplasms × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT02466971 2026-05-29

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

National Cancer Institute (NCI)

Phase 3 Active not recruiting
450 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡